Trial Profile
PERJETA IV Infusion Drug use surveillance
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Apr 2019
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- Sponsors Chugai Pharmaceutical
- 28 Nov 2017 Status changed from recruiting to completed.
- 30 May 2015 New trial record